ARID1A and cholangiocarcinoma: Furthermore, results from our study provide a sound basis and a unique opportunity for predicting favorable treatment responses to small molecule inhibitors of the PI3K/AKT pathway on ARID1A-mutated CCA which can improve treatment outcomes.